Role of oral teriflunomide in the management of multiple sclerosis

References

• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• StysPKZamponiGWvan MinnenJGeurtsJJWill the real multiple sclerosis please stand up?Nat Rev Neurosci201213750751422714021
   PubMed Web of Science ®Google Scholar
• EvangelouNThe only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: yesMult Scler201218121680168123235776
   PubMed Web of Science ®Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• FoxEJRhoadesRWNew treatments and treatment goals for patients with relapsing–remitting multiple sclerosisCurr Opin Neurol201225 SupplS11S1922398660
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med2010362541642620089960
   PubMed Web of Science ®Google Scholar
• KapposLRadueEMO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med201036238740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med201036240241520089954
   PubMed Web of Science ®Google Scholar
  Expert Opin Pharmacother201011101777178120408749
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• BruckWZamvilSSLaquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosisExpert Rev Clin Pharmacol20125324525622697588
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med2012366111000100922417253
   PubMed Web of Science ®Google Scholar
• LimmrothVMultiple sclerosis: oral BG12 for treatment of relapsing–remitting MSNat Rev Neurol20139181023147843
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• GasperiniCRuggieriSDevelopment of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod, will change therapeutic paradigm approachDrug Des Devel Ther20126175186
   PubMed Web of Science ®Google Scholar
• FontouraPGarrenHMultiple sclerosis therapies: molecular mechanisms and futureResults Probl Cell Differ20105125928520838962
   PubMedGoogle Scholar
• ChanECNewLSIn vitro metabolism of leflunomide by mouse and human liver microsomesDrug Metab Lett20071429930519356059
   PubMedGoogle Scholar
• HerrmannMLSchleyerbachRKirschbaumBJLeflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseasesImmunopharmacology2000472–327328910878294
   PubMed Web of Science ®Google Scholar
• TallantyreEEvangelouNConstantinescuCSSpotlight on teriflunomideInt MS J2008152626818782502
   PubMedGoogle Scholar
• PosevitzVChudykaDKurthFWiendlHTeriflunomide suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• Bar-OrAFreedmanMSKremenchutzkyMEffect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA study28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• KornTToykaKHartungHPJungSSuppression of experimental autoimmune neuritis by leflunomideBrain2001124Pt 91791180211522581
   PubMed Web of Science ®Google Scholar
• KornTMagnusTToykaKJungSModulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletionJ Leukoc Biol200476595096015328336
   PubMed Web of Science ®Google Scholar
• ZeydaMPoglitschMGeyereggerRDisruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formationArthritis Rheum20055292730273916142756
   PubMed Web of Science ®Google Scholar
• MattarTKochharKBartlettRBremerEGFinneganAInhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomideFEBS Lett199333421611648224241
   PubMed Web of Science ®Google Scholar
• MigitaKMiyashitaTIshibashiHSuppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1β stimulated rheumatoid synovial fibroblastsClin Exp Immunol2004137361261615320915
   PubMed Web of Science ®Google Scholar
• SiemaskoKChongASJackHMGongHWilliamsJWFinneganAInhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 productionJ Immunol19981604158115889469413
   PubMed Web of Science ®Google Scholar
• XuXWilliamsJWBremerEGFinneganAChongASInhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomideJ Biol Chem19952702112398124037759480
   PubMed Web of Science ®Google Scholar
• XuXWilliamsJWGongHFinneganAChongASTwo activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylationBiochem Pharmacol19965245275348759024
   PubMed Web of Science ®Google Scholar
• HoskinDWTaylorRMMakrigiannisAPJamesHLeeTDDose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte inductionInt J Immunopharmacol19982095055139818794
   PubMed Web of Science ®Google Scholar
• NwankwoEAllingtonDRRiveyMPEmerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosisDegener Neurol Neuromuscul Dis201221528
   Google Scholar
• DimitrovaPSkapenkoAHerrmannMLSchleyerbachRKaldenJRSchulze-KoopsHRestriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiationJ Immunol200216963392339912218161
   PubMed Web of Science ®Google Scholar
• DeageVBurgerDDayerJMExposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1β and metalloproteinasesEur Cytokine Netw1998946636689889411
   PubMed Web of Science ®Google Scholar
• ClaussenMCKornTImmune mechanisms of new therapeutic strategies in MS: teriflunomideClin Immunol20121421495621367665
   PubMed Web of Science ®Google Scholar
• MiljkovicDSamardzicTMostarica StojkovicMStosic-GrujicicSPopadicDTrajkovicVLeflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytesBrain Res20018891–233133811166726
   PubMed Web of Science ®Google Scholar
• HamiltonLCVojnovicIWarnerTDA771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive mannerBr J Pharmacol199912771589159610455314
   PubMed Web of Science ®Google Scholar
• JankovicVSamardzicTStosic-GrujicicSPopadicDTrajkovicVCell-specific inhibition of inducible nitric oxide synthase activation by leflunomideCell Immunol20001992738010698616
   PubMed Web of Science ®Google Scholar
• LiLLiuJZhangDJonesCTeriflunomide treatment of human monocyte-derived dendritic cells in vitro does not impair their maturation or ability to induce allogeneic T-cell responses28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• BartlettRRDimitrijevicMMattarTLeflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejectionAgents Actions1991321–210212058454
   PubMedGoogle Scholar
• Munier-LehmannHVidalainPOTangyFJaninYLOn dihydroorotate dehydrogenases and their inhibitors and usesJ Med Chem3202013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• LimsakunTMenguy-VacheronFPharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of MSAnnual Meeting of the American Academy of Neurology (AAN)April 10–17, 2010Toronto, ON, Canada
   Google Scholar
• RozmanBClinical pharmacokinetics of leflunomideClin Pharmacokinet200241642143012074690
   PubMed Web of Science ®Google Scholar
• LimVPandeILeflunomide can potentiate the anticoagulant effect of warfarinBMJ20023257376133312468482
   PubMed Web of Science ®Google Scholar
• TurpaultSMairSMengZHochetAMenguy-VacheronFEffect of teriflunomide on the pharmacodynamic and pharmacokinetic profiles of warfarin in healthy male subjects28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• BergnerRPetersLSchmittVLofflerCLeflunomide in dialysis patients with rheumatoid arthritis – a pharmacokinetic studyClin Rheumatol201332226727023179005
   PubMed Web of Science ®Google Scholar
• MerrillJEHanakSPuSFTeriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitisJ Neurol200925618910319169851
   PubMed Web of Science ®Google Scholar
• O’ConnorPWLiDFreedmanMSA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• O’ConnorPWFreedmanMSBar-OrARiceGPConfavreuxCTraboulseeAOral teriflunomide is effective and well tolerated in multiple sclerosis with relapses: results of an open-label 144-week extension study22nd Congress of the European Committee for the Treatment and Research in Multiple SclerosisSeptember 27–30, 2006Madrid, Spain
   Google Scholar
• O’ConnorPWolinskyJSConfavreuxCExtension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomisationFifth Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple SclerosisOctober 19–22, 2011Amsterdam, The Netherlands
   Google Scholar
• ConfavreuxCLiDKFreedmanMSLong-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 yearsMult Scler20121891278128922307384
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• MillerAEO’ConnorPWolinskyJSPre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisMult Scler201218111625163222723573
   PubMed Web of Science ®Google Scholar
• KapposLComiGConfavreuxCThe efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• Sanofi Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated November 5, 2012]. Available from: http://clinicaltrials.gov/show/NCT00622700. NLM identifier: NCT00622700Accessed March 1, 2013
   Google Scholar
• FreedmanMSWolinskyJSWamilBTeriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trialNeurology201278231877188522622860
   PubMed Web of Science ®Google Scholar
• FreedmanMWolinskyJSFranginGAOral teriflunomide or placebo added to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results62nd Annual Meeting of the American Academy of Neurology (AAN)April 10–17, 2010Toronto, ON, Canada
   Google Scholar
• Sanofi Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-β (TERACLES)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2010 [updated February 21, 2013]. Available from: http://clinicaltrials.gov/show/NCT01252355. NLM identifier: NCT01252355Accessed March 1, 2013
   Google Scholar
• VermerschPCzlonkowskaAGrimaldiLA multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon β-1a in patients with relapsing multiple sclerosisFourth Cooperative Meeting of CMSC and ACTRIMSMay 30–Jun 2, 2012San Diego, CA, USA
   Google Scholar
• AlcornNSaundersSMadhokRBenefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensingDrug Saf200932121123113419916579
   PubMed Web of Science ®Google Scholar
• RahmlowMShusterEADominikJLeflunomide-associated progressive multifocal leukoencephalopathyArch Neurol200865111538153919001176
   PubMed Web of Science ®Google Scholar
• CliffordDBAncesBCostelloCRituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritisArch Neurol20116891156116421555606
   PubMed Web of Science ®Google Scholar
• HarrisHEProgressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximabRheumatology (Oxford)200847222422518045807
   PubMed Web of Science ®Google Scholar
• SawadaTInokumaSSatoTLeflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritisRheumatology (Oxford)20094891069107219321513
   PubMed Web of Science ®Google Scholar
• ChambersCDJohnsonDLRobinsonLKBirth outcomes in women who have taken leflunomide during pregnancyArth Rheum20106251494150320131283
   PubMed Web of Science ®Google Scholar
• BrentRLTeratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a childTeratology200163210611211241434
   PubMedGoogle Scholar
• ComiGBenzerdjebHWangLTruffinetPO’ConnorPEffect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• WieseMDSchnablMO’DohertyCPolymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritisArthritis Res Ther2012144R16322784880
   PubMed Web of Science ®Google Scholar
• KieseierBBenamorMBenzerdjebHStuveOPregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS)October 10–13, 2012Lyon, France
   Google Scholar
• FreedmanMSConfavreuxCComiGHair thinning associated with teriflunomide therapy is manageableFourth Cooperative Meeting of CMSC and ACTRIMSMay 30–Jun 2, 2012San Diego, CA, USA
   Google Scholar
• BalakDMHengstmanGJCakmakAThioHBCutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewMult Scler201218121705171722371220
   PubMed Web of Science ®Google Scholar
• KillesteinJRudickRAPolmanCHOral treatment for multiple sclerosisLancet Neurol201110111026103422014437
   PubMed Web of Science ®Google Scholar
• BioTrends Research GroupTreatmentTrends^®: Multiple Sclerosis (US) 2012Exton, PABioTrends Research Group2012 Available from: http://bio-trends.com/Images---Files/Products-and-Services/Products/TT-Report-Overviews/2011-Report-Overviews/TreatmentTrends/TreatmentTrends-Multiple-Sclerosis-in-the-US-1-5-1.aspxAccessed March 22, 2013
   Google Scholar
• BioTrends Research GroupPatientTrends^®: Multiple Sclerosis (US) 2012Exton, PABioTrends Research Group2012 Available from: http://bio-trends.com/Images---Files/Products-and-Services/Products/TT-Report-Overviews/2011-Report-Overviews/PatientTrends/PatientTrends-Multiple-Sclerosis-1-17-12.aspxAccessed March 22, 2013
   Google Scholar
• O’ConnorPBriggsACaritaPBego-Le-BagousseGImpact on health-related quality of life of teriflunomide treatment by estimating utilities in patients with relapsing multiple sclerosis: results from TEMSO post hoc analysisAnnual Meeting of the European Neurological Society (ENS)June 9–12, 2012Prague, Czech Republic.
   Google Scholar
• VermerschPCzlonkowskaAGrimaldiLEvaluation of patient satisfaction from the TENERE study: a comparison of teriflunomide and subcutaneous interferon β-1a in patients with relapsing multiple sclerosisAnnual Meeting of the European Neurological Society (ENS)June 9–12, 2012Prague, Czech Republic
   Google Scholar
• GoldRWolinskyJSPathophysiology of multiple sclerosis and the place of teriflunomideActa Neurol Scand20111242758420880295
   PubMed Web of Science ®Google Scholar
• NoyesKBajorskaAChappelACost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based studyNeurology201177435536321775734
   PubMed Web of Science ®Google Scholar
• TrojanoMPellegriniFPaolicelliDFuianiADi RenzoVObservational studies: propensity score analysis of non-randomized dataInt MS J2009163909719878631
   PubMedGoogle Scholar
• HeDXuZDongSTeriflunomide for multiple sclerosis [review]Cochrane Database Syst Rev201212CD00988223235682
   PubMed Web of Science ®Google Scholar
• FreedmanMSWolinskyJSByrnesWJOral teriflunomide or placebo added to interferon beta for months in patients with relapsing multiple sclerosis: safety and efficacy results25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)September 9–12, 2009Dusseldorf, Germany
   Google Scholar